https://www.selleckchem.com/products/OSI-906.html
trate compliance with regulatory requirements for accuracy of chemistry testing on NSBF samples. Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are active as single agents and in combination with cytotoxic chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Given each drug's single agent activity and unique mechanism of action, we aimed to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic HNSCC. This study is an open-label, non-randomised
Like
Comment
Share
